NCT02914626View on ClinicalTrials.gov

Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

PHASE3UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2018

Conditions
Glaucoma, NeovascularRanibizumab
Interventions
DRUG

Intravitreal ranibizumab

Intravitreal ranibizumab injection

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

LEANDRO CABRAL ZACHARIAS

OTHER